However, a recent analysis has shown that risk of death or AIDS events follow a CD4+ T-cell count gradient in ART-treated participants, with clear risk for counts below 200 cells/μl but still some benefit for those individuals with a CD4+ T-cell count at least 500 cells/μl [9]. The gene discussed is CD4; the disease is AIDS.